Publication: Inhibition of proteolytic and hemorrhagic activities by ethyl acetate extract of Eclipta prostrata against Malayan pit viper venom
Issued Date
2007-04-01
Resource Type
ISSN
17445116
13880209
13880209
Other identifier(s)
2-s2.0-34347387551
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Biology. Vol.45, No.4 (2007), 282-288
Suggested Citation
Pimolpan Pithayanukul, Bunmun Lapett, Rapepol Bavovada, Narumol Pakmanee, Rutt Suttisri Inhibition of proteolytic and hemorrhagic activities by ethyl acetate extract of Eclipta prostrata against Malayan pit viper venom. Pharmaceutical Biology. Vol.45, No.4 (2007), 282-288. doi:10.1080/13880200701214805 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/24223
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Inhibition of proteolytic and hemorrhagic activities by ethyl acetate extract of Eclipta prostrata against Malayan pit viper venom
Other Contributor(s)
Abstract
The ethyl acetate extract of Eclipta prostrata L. (Asteraceae) was evaluated for its antivenom potential against Calloselasma rhodostoma Kuhl (Viperidae) (Malayan pit viper; MPV) venom. The partially purified ethyl acetate extract (PEE) was found to contain 47% wedelolactone as its major constituent. PEE and wedelolactone demonstrated strong antiproteolytic and antihemorrhagic activities against MPV venom in a dose-dependent manner. The extract, at 5 mg/mL, could inhibit proteolytic activity of 100 μg of the venom and hemorrhagic activity of 3 minimum hemorrhagic doses (MHD) to 95% and 68%, respectively. At the same concentration, wedelolactone could neutralize the proteolytic activity at around 76% and, at doses of 0.25-1 mg/mL, offered protection against hemorrhagic activity of the venom in the range 3-35%. Both PEE and wedelolactone displayed partial anti-phospholipase A2 activity (21% for PEE and 7% for wedelolactone) and could not neutralize the lethal effect of either 2LD50 or 4LD50 of MPV venom. © 2007 Informa Healthcare.